세계의 면역치료제 시장 규모는 2025년 2,607억 달러로 추정되고, 2025-2030년 예측 기간 동안 CAGR 12.4%로 추이할 전망이며, 2030년 말에는 4,674억 달러에 이를 것으로 예측됩니다.
북미 시장은 2025년 1,454억 달러로 추정되고, 2025-2030년 예측 기간 동안 CAGR 12.6%로 추이할 전망이며, 2030년 말에는 2,628억 달러에 이를 것으로 예측됩니다. 유럽 시장은 2025년 607억 달러로 추정되고, 2025-2030년 예측 기간 동안 CAGR 11.2%로 추이할 전망이며, 2030년 말에는 1,035억 달러에 이를 것으로 예측됩니다.
본 보고서에서는 세계의 면역치료제 시장을 조사했으며, 시장 개요, 시장영향인자 및 시장기회 분석, 기술 동향, 법규제 환경, 시장 규모 추이 및 예측, 각종 구분, 지역별 상세 분석, 주요기업의 프로파일 등을 정리했습니다.
목차
제1장 주요 요약
시장 전망
조사 범위
시장 요약
시장 역학 및 성장요인
신흥 기술
부문 분석
지역 분석
결론
제2장 시장 개요
개요
거시경제 요인분석
미국 관세의 제약 업계에 미치는 영향
의료비
GDP가 제약업계에 미치는 영향
Porter's Five Forces 분석
제3장 시장 역학
시장 역학
시장 성장 촉진요인
만성질환의 발생률 증가
기업에 의한 연구개발비 증가
정부자금 및 의약품 연구개발비 증가
시장 성장 억제요인
면역치료제의 고비용
제네릭 의약품의 경쟁 격화
숙련된 전문가의 부족
시장 기회
면역치료에 있어서 기술의 진보
면역치료의 가능성
제4장 규제 상황
개요
미국
유럽
아시아태평양
제5장 신기술 및 파이프라인 분석
개요
AI 및 머신러닝
신흥 바이오마커
유전자 편집 및 CRISPR
파이프라인 분석
특허 분석
제6장 시장 부문 분석
세분화의 내역
세계의 면역치료제 시장 : 치료 유형별
중요 포인트
단일클론항체
체크포인트 억제제
사이토카인
기타
세계의 면역치료제 시장 : 용도별
중요 포인트
암
자가면역질환
만성 염증성 호흡기 질환
지리적 내역
세계의 면역치료제 시장 :지역별
중요 포인트
북미
유럽
아시아태평양
남미
중동 및 아프리카
제7장 경쟁 정보
중요 포인트
경쟁 구도
기업 점유율 분석
제8장 면역치료제 시장에서의 지속가능성 : ESG의 관점
ESG 입문
면역치료제 시장에서의 지속가능성
ESG의 관점
환경에 미치는 영향
사회에 미치는 영향
거버넌스의 영향
ESG 위험 평가
결론
제9장 부록
조사 방법
약어
출처
기업 프로파일
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
GSK PLC.
JOHNSON & JOHNSON SERVICES INC.
LILLY
MERCK & CO.INC.
NOVARTIS AG
PFIZER INC.
SANOFI
TAKEDA PHARMACEUTICAL CO. LTD.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
신흥 기업
AJY
영문 목차
영문목차
The global immunotherapy drugs market is expected to grow from $260.7 billion in 2025 and is projected to reach $467.4 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.4% during the forecast period of 2025 to 2030.
The North American immunotherapy drugs market is expected to grow from $145.4 billion in 2025 and is projected to reach $262.8 billion by the end of 2030, at a CAGR of 12.6% during the forecast period of 2025 to 2030.
The European immunotherapy drugs market is expected to grow from $60.7 billion in 2025 and is projected to reach $103.5 billion by the end of 2030, at a CAGR of 11.2% during the forecast period of 2025 to 2030.
Report Scope
The current report provides detailed information on immunotherapy drugs. It analyzes the market trends with data from 2024, estimates for 2025 and projections of compound annual growth rates (CAGRs) from 2025 through 2030, including regional markets for immunotherapy drugs. This report highlights the current and future market potential and provides a detailed discussion on the competitive environment. The report will also cover regulatory scenarios, drivers, restraints and opportunities. Additionally, it covers market share data for key companies.
The market in this report is segmented by immunotherapy type into checkpoint inhibitors, monoclonal antibodies (mAbs) and cytokine therapy. MAbs are sub-segmented into naked mAbs, conjugated mAbs and bispecific mAbs. Checkpoint inhibitors are sub-segmented into programmed cell death protein 1 (PD-1), cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death ligand 1 (PD-L1) and lymphocyte activation gene 3 (LAG-3).
By application, the market is segmented into cancer, autoimmune diseases and chronic inflammatory diseases.
By region, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa (MEA), and South America. The regional segment will cover a detailed analysis of the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China, South Korea, Australia and India. Market data is provided for 2024 the base year, with forecasts for 2025 and a forecast value for 2030.
The report aims to:
Analyze types of immunotherapies.
Analyze global market size and segmentation.
Understand market constraints and drivers.
Provide detailed market forecasts through 2030.
Assess market shares, competitiveness and industry structure.
Identify potential long-term impacts on the immunotherapy drug market.
Report Includes
88 data tables and 57 additional tables
An overview of the global market for immunotherapy drugs
In-depth analysis of global market trends, featuring historical revenue data for 2022-2024, estimated figures for 2025, and forecasts for 2030, including projections of CAGRs through 2030
Evaluation of the current market size and revenue growth prospects specific to the immunotherapy drugs, accompanied by a market share analysis by therapy type, application and region
Description of immunotherapy and combination immunotherapy, and discussion of how it targets cell-mediated adaptive immunity
Details of checkpoint inhibitors, monoclonal antibodies, interleukins and interferons; and coverage of innovative strategies and new targeted approaches for immunotherapy
Analysis of the current and future demands in the global immunotherapy drugs, along with a detailed analysis of the competitive environment, market regulations and reimbursement practices
Analysis of drivers, challenges and opportunities affecting the market's growth
Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, new product pipeline, regulatory framework and reimbursement scenarios, and ESG trends of the market
Market share analysis of the key companies in the immunotherapy drugs, along with their research priorities, product portfolios, global rankings and the competitive landscape
Profiles of major companies in industry, including F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, and Sanofi
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion
Chapter 2 Market Overview
Overview
Macroeconomic Factor Analysis
Impact of U.S. Tariffs on the Pharmaceutical Industry
Healthcare Expenditure
Impact of GDP on the Pharma Sector
Porter's Five Forces Analysis
Bargaining Power of Buyers
Bargaining Power of Suppliers
Potential for New Entrants
Threat of Substitutes
Competitiveness in the Industry
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Increasing Incidence of Chronic Diseases
Increasing R&D Spending by Market Players
Rise in Government Funding and Pharmaceutical R&D Spending
Market Restraints
High Cost of Immunotherapy Drugs
Rising Generic Competition
Lack of Skilled Professionals
Market Opportunities
Technological Advances in Immunotherapy
Potential in Immunotherapy
Chapter 4 Regulatory Landscape
Overview
U.S.
Europe
Asia-Pacific
Chapter 5 Emerging Technologies and Pipeline Analysis
Overview
AI and ML
Emergent Biomarkers
Genome Editing and CRISPR
Pipeline Analysis
Key Takeaways
Patent Analysis
Key Takeaways
Chapter 6 Market Segment Analysis
Segmentation Breakdown
Global Market for Immunotherapy Drugs, by Therapy Type
Key Takeaways
Monoclonal Antibodies
Checkpoint Inhibitors
Cytokines
Others
Global Immunotherapy Drug Market, by Application
Key Takeaways
Cancer
Autoimmune Diseases
Chronic Inflammatory Respiratory Condition
Geographic Breakdown
Global Market for Immunotherapy Drugs by Region
Key Takeaways
North America
Europe
Asia-Pacific
South America
Middle East and Africa
Chapter 7 Competitive Intelligence
Key Takeaways
Competitive Landscape
Company Share Analysis
Chapter 8 Sustainability in Immunotherapy Drugs Market: An ESG Perspective
Introduction to ESG
Sustainability in the Immunotherapy Drug Market
ESG Perspective
Environmental Impact
Social Impact
Governance Impact
ESG Risk Ratings
Conclusion
Chapter 9 Appendix
Methodology
Abbreviations
Sources
Company Profiles
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
GSK PLC.
JOHNSON & JOHNSON SERVICES INC.
LILLY
MERCK & CO.INC.
NOVARTIS AG
PFIZER INC.
SANOFI
TAKEDA PHARMACEUTICAL CO. LTD.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Emerging Players in the Immunotherapy Drugs Market
